Soluble guanylate cyclase (sGC) and its product, cyclic guanosine monophosphate, play a
role in learning and memory formation. Zagociguat (CY6463) is a novel stimulator of sGC …

Abstract Introduction Gln‐1062 (MEMOGAIN) is an intranasally administered lipophilic
prodrug of galantamine. Based on high brain‐to‐blood concentrations observed in pre …

Selective M1 muscarinic acetylcholine receptor (mAChR) agonists are being developed as
symptomatic treatment for neurodegenerative and neuropsychiatric disorders that lead to …

Novel therapeutic agents targeting the central cholinergic system are under development. In
early phase development studies in healthy volunteers biomarkers are used to proof …

The pharmaceutical industry has been suffering from low success rates on the approval of
new drugs. One of the main attrition is found in the early clinical development. This problem …

Aims HTL0009936 is a selective M1 muscarinic receptor agonist in development for
cognitive dysfunction in Alzheimer's disease. Safety, tolerability and pharmacokinetics and …

Soluble guanylyl cyclase (sgc) and its product, cyclic guanosine monophosphate play a role
in learning and memory formation. Zagociguat (cy6463) is a novel stimulator of sgc being …

Background: The cholinergic system and M1 receptor remain an important target for
symptomatic treatment of cognitive dysfunction. The selective M1 receptor partial agonist …

Selective M1 muscarinic acetylcholine receptor (mAChR) agonists are being developed as
symptomatic treatment for neurodegenerative and neuropsychiatric disorders that lead to …